Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 13Terminated 6Recruiting 6Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 65Breast 16Head & Neck 11Tumor-Agnostic 2Thoracic 2Other solid neoplasm 2CNS 1

Conditions

Brain Neoplasms 1

Interventions

Temozolomide 20Magnetic Resonance Spectroscopy 10Radiotherapy 9Blood Specimen Collection 8pembrolizumab 6Cyclophosphamide 6Bevacizumab 6AZD 6244 6Radiation 5Specimen Handling 4vorasidenib 3fludarabine 3cemiplimab 3aflutinib 3Surgical Procedures, Operative 3Saline Solution 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Pemetrexed 3Granulocyte-Macrophage Colony-Stimulating Factor 3tislelizumab 2osimertinib 2naxitamab 2gallium maltolate 2fludarabine phosphate 2dinutuximab 2Topotecan 2Standard of Care 2Spinal Puncture 2Receptors, Interleukin-8B 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Capecitabine × CNS × Clear all
NCT06374888 2024-04-19

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
28 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡